Navigation Links
InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
Date:11/5/2009

und RG7227 (ITMN-191) which entered Phase 2b in August of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon this data, in combination with the other efficacy and safety results the company currently has submitted in support of its NDA file and plans to submit in support of its MAA filing. Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) the fact that physician prescriptions of Actimmune for the treatment of IPF, an indication for which Actimmune has not been approved by the FDA, have declined significantly fol
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  iMD Companies, Inc. (ICBU) has repositioned itself as ... and grab a foothold in the hydroponic, hemp and medical ... a presence in the sector, and recently partnering with the ... hemp and medical marijuana, iMD is committing to bring its ...
(Date:1/23/2015)... LAS VEGAS , Jan. 23, 2015 Cord Blood ... CBAI ) ("CBAI" or the "Company")  filed a Preliminary Proxy ... ( www.sec.gov ) today, and provides an update for shareholders ... authorized shares is requested. Dear Shareholders, ...
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
Breaking Medicine Technology:iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
... Mass., Aug. 31, 2011 Syndax Pharmaceuticals, Inc ... management will present at the following upcoming fall financial ... New York, NY, September 8 at 8:30 AM ET ... Zurich, Switzerland, September 13, 11:15 AM CEST oncology panel ...
... Fla., Aug. 31, 2011 A recent study featured ... dispels the myth that physicians, offices use prostate cancer ... The article, "Utilization Trends in Prostate Cancer ... of both surgical and radiation therapy for management of ...
Cached Medicine Technology:Syndax Pharmaceuticals to Present at Upcoming Fall Financial Conferences 2Study Explores Utilization Trends for Prostate Cancer Treatments 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 Woodloch Pines, an ... has been selected by TripAdvisor as the number one best ... 6th best in the world for their annual Travelers’ Choice ... travel community . The website is home to millions of ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 VogueQueen is a ... affordable prices and many designers are thrilled to have it ... business announces its new collection of prom dresses for the ... to drive the strategic vision and he focuses on continuing ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) ... to “Live Fearless.” , The “Faces of Fearless” ... about how they or someone they know has faced a ... the moment. By telling these types of stories through livefearlessmn.com, ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Juvent Sports ... at the 2015 PGA Merchandise Show to bestow a ... incredible female amateur golfer, Arlene McKitrick. The award commemorated ... amateur golf tournament win. She won her first amateur ...
(Date:1/22/2015)... has released a new blog post explaining the main features ... , Auto insurance quotes help many drivers find the best ... call an agent or visit an agency for price information. ... http://autocarinsurancebest.com/ . , Every business who relies heavily on ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Commercial Auto Insurance Provides Several Important Features! 2
... in minimally invasive surgical techniques -- most notably, ... common surgical option across the United States for ... , A newer, third option is a hybrid ... safe and effective and compares favorably with standard ...
... Software Complies with 100% of Updated Interoperability RequirementsTAMPA, ... a leading provider of electronic health records, today ... Technology (CCHIT(R)) has approved Sage,s product, Sage Intergy ... Ambulatory EHR , additionally certified ...
... Managing Turnover According to Cejka Search and AMGA ... to the current economic crisis is that physicians ... However, with the physician shortage intensifying and ... sharpening their competitive edge in finding and keeping ...
... surgical approach to treat stomach cancer has been shown ... treatment for some patients. , A new study led ... traditional "open" surgery to remove the stomach with laparoscopic ... surgeon removes the stomach while guided by a magnified ...
... thyroid cancer is being held today at the United Nations ... of thyroid cancer among millions of people around the world ... in Ukraine on April 26, 1986. ... (NYEEI) is working in partnership with Project Chernobyl, a ...
... Therapeutics, Inc. announced today positive results from a ... evaluating fenretinide for the treatment of geographic atrophy ... analysis was triggered when all patients had reached ... http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO )The analysis compared the ...
Cached Medicine News:Health News:Helping hand of hybrid surgery benefits colorectal patients 2Health News:Sage Intergy EHR Receives 08 CCHIT Certification 2Health News:Sage Intergy EHR Receives 08 CCHIT Certification 3Health News:Sage Intergy EHR Receives 08 CCHIT Certification 4Health News:Sage Intergy EHR Receives 08 CCHIT Certification 5Health News:The Economy Plus Flexibility Keep Physicians in Practice 2Health News:The Economy Plus Flexibility Keep Physicians in Practice 3Health News:The Economy Plus Flexibility Keep Physicians in Practice 4Health News:New minimally invasive surgery option for patients with stomach cancer 2Health News:'Living With Radiation' Conference Commemorating Chernobyl Nuclear Disaster Held at United Nations, Sponsored by New York Eye & Ear Infirmary 2Health News:Sirion Therapeutics Announces Positive Results From Interim Analysis of Phase II Trial and Receives FDA Fast Track Designation for Fenretinide 2Health News:Sirion Therapeutics Announces Positive Results From Interim Analysis of Phase II Trial and Receives FDA Fast Track Designation for Fenretinide 3
Includes conservation device, matched regulator, standard supply tubing, cannula, carrying case, batteries, and instruction booklet....
... Control Catheter with Accutrol is similar in ... except that it incorporates a temperature probe ... The temperature probe can accurately determine the ... catheter provides temperature accuracy comparable to a ...
... Through A 1.0mm Incision., ,Special Direct Acting ... Improved ... Approach., ,Recessed Jaws For Improved Sub-Incisional Flap ... Jaws During Sterilization., ,Reusable, Autoclaveable, Guaranteed For ...
... Special Reverse-Action Forceps Design With Spreading Spatula ... The Spreading & Lifting Of Corneal Flaps Created ... ,The Spatula Tips Of ... The Corneal Flap. Once Access Is Achieved, ...
Medicine Products: